Post
The Wall Street Journal
wsj.com
did:plc:i3fhjvvkbmirhyu4aeihhrnv
The combination of Roche’s investigational drug, giredestrant, with Pfizer’s Ibrance didn’t lead to a statistically significant improvement among patients with advanced breast cancer. on.wsj.com/4rZrLcT
https://on.wsj.com/4rZrLcT
2026-03-09T06:39:04.856Z